Edition:
United States

Vermillion Inc (VRML.OQ)

VRML.OQ on NASDAQ Stock Exchange Capital Market

1.93USD
11 Dec 2017
Change (% chg)

$0.12 (+6.63%)
Prev Close
$1.81
Open
$1.80
Day's High
$2.09
Day's Low
$1.77
Volume
57,119
Avg. Vol
14,397
52-wk High
$2.85
52-wk Low
$0.91

Chart for

About

Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's... (more)

Overall

Beta: 2.29
Market Cap(Mil.): $108.60
Shares Outstanding(Mil.): 60.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Vermillion reports third quarter loss of $0.06 per share

* Qtrly net loss per share attributable to common stockholders basic and diluted $0.06‍​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Nov 08 2017

BRIEF-‍Aspira Labs says has entered into agreements to provide coverage for OVA1​

* ‍Aspira Labs says has entered into agreements to provide coverage for its in vitro diagnostic test, OVA1​

Oct 27 2017

BRIEF-Vermillion to report Q3 results on Nov 8

* Vermillion to report third quarter 2017 financial results and host investor conference call on November 8th Source text for Eikon: Further company coverage:

Oct 25 2017

BRIEF-Vermillion files for mixed shelf of up to $50 mln - SEC filing

* Vermillion files for mixed shelf of up to $50 million - SEC filing Source text for Eikon: Further company coverage:

Oct 24 2017

BRIEF-Aspira Labs announces in-network contract agreement with Healthnet Federal Services for OVA1

* Aspira Labs announces in-network contract agreement with Healthnet Federal Services for OVA1

Oct 02 2017

BRIEF-Vermillion reports Q2 loss per share $0.04

* Q2 revenue rose 27 percent to $898,000 Source text for Eikon: Further company coverage:

Aug 09 2017

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $54.94 +0.30
Becton Dickinson and Co (BDX.N) $218.31 -1.37
Arrayit Corp (ARYC.PK) $0.01 +0.00

Earnings vs. Estimates